RAF1 and neoplasm: Sorafenib is an orally administered multikinase inhibitor that decreases tumor cell proliferation by blocking Raf-1, wild-type B-Raf and the mitogen-activated protein kinase (MAPK) extracellular signaling-regulated kinase (ERK) signaling pathway.